Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GPX3
REST API REST API
Homo sapiens
GPX3 is differentially expressed in 322 experiments: 166 organism parts: kidney, lung, ... (164 more);, 250 disease states: normal, prostate carcinoma, ... (248 more);, 105 cell types 499 cell lines 43 compound treatments and 64 other conditions.
Orthologs Gpx3 (Mus musculus)   F1NXZ1_CHICK (Gallus gallus)   gpx3 (Danio rerio)   F6X863_CIOIN (Ciona intestinalis)   GPX1 (Saccharomyces cerevisiae)   GPX3 (Bos taurus)   Gpx3 (Rattus norvegicus)   HYR1 (Saccharomyces cerevisiae)   gpx3 (Xenopus laevis)   GPX2 (Saccharomyces cerevisiae)   (Compare orthologs)
Gene Ontology Term response to oxidative stress, glutathione peroxidase activity, glutathione binding, hydrogen peroxide catabolic process, soluble fraction, glutathione metabolic process, response to drug, response to corticosterone stimulus, female pregnancy, response to molecule of fungal origin, response to selenium ion, response to organic substance, oxidation-reduction process, response to organic cyclic compound
InterPro Term Glutathione_peroxidase
UniProt Accession Q6NXQ3, P22352, E5RJS2, E5RHK5
Search EB-eye ENSG00000211445
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7224, E-GEOD-2549, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
BT474
3
E-MEXP-440, E-MTAB-37, E-MTAB-62
MDA-MB-231
3
E-TABM-420, E-MTAB-62, E-GEOD-5823
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
Jurkat
2
E-GEOD-1880, E-MTAB-62
H1437
2
E-GEOD-16194, E-MTAB-62
493 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (53 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-10797, E-MEXP-2034
2
E-TABM-145, E-TABM-130
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
hematopoietic stem cell
2
E-MEXP-872, E-MEXP-1403
CD3- CD56dim CD62L+ NK cell
1
E-GEOD-21774
99 more value(s).


Disease state

studied in E-GEOD-3307, E-TABM-15, E-MTAB-62, E-MTAB-680, E-GEOD-2113, ... (72 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-MTAB-62, E-GEOD-96, E-MEXP-2034, E-MEXP-1327, E-GEOD-3868 ... (5 experiments)
chronic myelogenous leukemia
3
E-GEOD-5550, E-MTAB-62, E-MTAB-37
glioblastoma
1
3
E-MTAB-37, E-MTAB-62, E-GEOD-4412, E-GEOD-6014
lung adenocarcinoma
1
3
E-GEOD-2514, E-MTAB-37, E-MTAB-62, E-MEXP-231
myeloma
2
E-MTAB-37, E-MTAB-62
prostate cancer
2
E-GEOD-6919, E-MTAB-62
244 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (29 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
TNF
1
E-GEOD-15205
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
nebivolol
1
E-GEOD-3356
non-steroidal anti-inflammatory drugs
1
E-GEOD-1919
untreated
1
E-GEOD-15389
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-4667, ... (7 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-7788, E-GEOD-2509, E-GEOD-22148, ... (8 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-6919, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (7 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-18005, E-TABM-868, E-TABM-601, E-GEOD-2841, ... (14 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-12773, E-GEOD-20504, E-MEXP-1446, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-GEOD-1926, E-GEOD-16363, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (8 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.453 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM